Pyrotinib
As of the edition of 20 October 2026, Pyrotinib is a small molecule: in active development; acts on EGFR and ERBB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 178, 2 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Digestive system; Nervous system; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 25 | 3 | 10 | 0 |
| Phase 1 | 11 | 7 | 1 | 0 |
| Phase 2 | 118 | 4 | 48 | 2 |
| Phase 3 | 20 | 2 | 13 | 0 |
| Phase 4 | 4 | 0 | 4 | 0 |
| All trials | 178 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2013 to now |
| Hengrui Therapeutics | Lead sponsor of trials | 2015 to now |
| Qingdao Zhixin Health Technology | Lead sponsor of trials | 2020 to now |
| Risen Pharma Tech | Lead sponsor of trials | 2024 to now |
| RemeGen | Lead sponsor of trials | 2027 to now |